Compare CSTM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | IMNM |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2013 | 2020 |
| Metric | CSTM | IMNM |
|---|---|---|
| Price | $18.40 | $19.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $19.50 | ★ $26.89 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $7,969,000,000.00 | $9,679,000.00 |
| Revenue This Year | $9.43 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | $23.50 | ★ N/A |
| Revenue Growth | ★ 11.22 | N/A |
| 52 Week Low | $7.33 | $5.15 |
| 52 Week High | $18.75 | $20.80 |
| Indicator | CSTM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 58.69 |
| Support Level | $17.20 | $18.87 |
| Resistance Level | $18.34 | $20.80 |
| Average True Range (ATR) | 0.65 | 1.22 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 90.00 | 70.80 |
Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.